PERIPHERAL-BLOOD PROGENITOR SUPPORTED HIGH-DOSE CHEMOTHERAPY - DETERMINATION OF A THRESHOLD NUMBER OF CD34+ CELLS FOR RELIABLE ENGRAFTMENT

被引：0
|
作者：
RAPTIS, G [1 ]
VAHDAT, L [1 ]
FENNELLY, D [1 ]
REICH, L [1 ]
HAMILTON, N [1 ]
YAO, TJ [1 ]
BENGALA, C [1 ]
SCHNEIDER, J [1 ]
SHAPIRO, F [1 ]
GULATI, S [1 ]
NORTON, L [1 ]
CROWN, J [1 ]
机构：
[1] MEM SLOAN KETTERING CANC CTR,NEW YORK,NY
来源：
BLOOD | 1993年 / 82卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A289 / A289
页数：1
相关论文
共 50 条
  • [21] Infusion of CD34 enriched peripheral blood progenitor cells result in rapid engraftment after high-dose chemotherapy in patients with advanced lymphoma.
    Koc, ON
    Gerson, SL
    Fox, RM
    Schupp, JE
    Marko, DA
    Steckley, JA
    Lazarus, HM
    BLOOD, 1995, 86 (10) : 917 - 917
  • [22] Preapheresis levels of peripheral blood CD34+ cells correlate with CD34+ peripheral blood progenitor cells in autologous patients
    Areman, EM
    Meehan, KR
    Sacher, RA
    TRANSFUSION, 1997, 37 (11-12) : 1217 - 1217
  • [23] Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation
    Pérez-Simón, JA
    Caballero, MD
    Corral, M
    Nieto, MJ
    Orfao, A
    Vazquez, L
    Amigo, ML
    Berges, C
    González, M
    Del Cañizo, C
    San Miguel, JF
    TRANSFUSION, 1998, 38 (04) : 385 - 391
  • [24] TANDEM CYCLES OF HIGH-DOSE CHEMOTHERAPY (HDC) SUPPORTED WITH G-CSF PRIMED PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC)
    MEISENBERG, B
    MILLER, W
    MCMILLAN, R
    BLOOD, 1994, 84 (10) : A715 - A715
  • [25] Mobilization of peripheral blood progenitor cells (PBPC) and engraftment following high-dose chemotherapy for AIDS-lymphoma
    Krishnan, A
    Molina, A
    Zaia, J
    Nademanee, A
    Levine, A
    Sniecinski, I
    Li, S
    Brent, J
    Woo, D
    Kogut, N
    Forman, SJ
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 23 (03) : A29 - A29
  • [26] High-dose therapy in patients with Hodgkin's disease:: the use of selected CD34+ cells is as safe as unmanipulated peripheral blood progenitor cells
    Blystad, AK
    Holte, H
    Kvaloy, S
    Smeland, E
    Delabie, J
    Kvalheim, G
    BONE MARROW TRANSPLANTATION, 2001, 28 (09) : 849 - 857
  • [27] High-dose therapy in patients with Hodgkin's disease: the use of selected CD34+ cells is as safe as unmanipulated peripheral blood progenitor cells
    AK Blystad
    H Holte
    S Kvaløy
    E Smeland
    J Delabie
    G Kvalheim
    Bone Marrow Transplantation, 2001, 28 : 849 - 857
  • [28] TRANSPLANTATION OF CD34 POSITIVE(+) MARROW AND OR PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) INTO BREAST-CANCER PATIENTS FOLLOWING HIGH-DOSE CHEMOTHERAPY (HDC)
    BERENSON, RJ
    SHPALL, EJ
    FRANKLIN, W
    BEARMAN, SI
    STEMMER, S
    PURDY, MH
    TAFFS, SR
    HEIMFELD, S
    JONES, RB
    BLOOD, 1993, 82 (10) : A173 - A173
  • [29] THRESHOLD DOSE OF AUTOLOGOUS CD34-POSITIVE PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) REQUIRED FOR ENGRAFTMENT AFTER MYELOABLATIVE TREATMENT FOR MULTIPLE-MYELOMA
    SCHILLER, G
    ROSEN, L
    VESCIO, R
    SPITZER, G
    FREYTES, C
    LILL, M
    LEE, M
    BERENSON, R
    BERENSON, J
    BLOOD, 1994, 84 (10) : A207 - A207
  • [30] EXPANSION OF CD34+ CELLS ISOLATED FROM CRYOPRESERVED MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC)
    ALCORN, MJ
    HOLYOAKE, TL
    RICHMOND, LJ
    PEARSON, C
    FARRELL, E
    KYLE, B
    DUNLOP, D
    FITZSIMONS, EJ
    PRAGNELL, IB
    FRANKLIN, IM
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 909 - 909
12345